


Cisatracurium besylate

| | |
|---------------------------|--|
| Cat. No.: | HY-13596 |
| CAS No.: | 96946-42-8 |
| Molecular Formula: | C ₆₅ H ₈₂ N ₂ O ₁₈ S ₂ |
| Molecular Weight: | 1243.48 |
| Target: | nAChR; Autophagy |
| Pathway: | Membrane Transporter/Ion Channel; Neuronal Signaling; Autophagy |
| Storage: | 4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |



SOLVENT & SOLUBILITY

| | | | | | | |
|---|--|--------------------------|-----------|-----------|-----------|-----------|
| In Vitro | H ₂ O : ≥ 50 mg/mL (40.21 mM) * "≥" means soluble, but saturation unknown. | | | | | |
| | | Solvent Concentration | Mass | | | |
| | Preparing Stock Solutions | 1 mM | | 1 mg | 5 mg | 10 mg |
| | | 5 mM | | 0.1608 mL | 0.8042 mL | 1.6084 mL |
| 10 mM | | | 0.0804 mL | 0.4021 mL | 0.8042 mL | |
| Please refer to the solubility information to select the appropriate solvent. | | | | | | |
| In Vivo | 1. Add each solvent one by one: PBS Solubility: 100 mg/mL (80.42 mM); Clear solution; Need ultrasonic | | | | | |

BIOLOGICAL ACTIVITY

| | |
|-------------------------------------|---|
| Description | Cisatracurium besylate (51W89) is a nondepolarizing neuromuscular blocking agent, antagonizing the action of acetylcholine by inhibiting neuromuscular transmission. |
| IC₅₀ & Target | AChR alpha-2 ^{[1][2]} . |
| In Vitro | Cisatracurium Besylate (51W89) is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is a bisbenzyltetrahydroisoquinolinium agent with an intermediate duration of action. Cisatracurium Besylate (51W89) is one of the ten isomers of the parent molecule, atracurium. Moreover, cisatracurium represents approximately 15% of the atracurium mixture [1, 2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

CUSTOMER VALIDATION

- Int Immunopharmacol. 2023 May 12;120:110291.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Dear, G.J., et al., Identification of urinary and biliary conjugated metabolites of the neuromuscular blocker 51W89 by liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom, 1995. 9(14): p. 1457-64.
- [2]. Serra, C.S. and A.C. Oliveira, Cisatracurium: myographical and electrophysiological studies in the isolated rat muscle. Fundam Clin Pharmacol, 2006. 20(3): p. 291-8.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA